SU2C awards $1 million to four research teams through Phillip A. Sharp Awards

NCI faces prospect of an 11% cut in FY25—another setback in a period of tight budgets and sliding paylines

After a year of lean appropriations, NCI is looking at what threatens to be a budgetary cataclysm—a potential 10-11% cut to the Labor-HHS spending bill in fiscal year 2025.

June 14, 2024

Vol.50 No.24

By Matthew Bin Han Ong

Obituary

“Father of tamoxifen” V. Craig Jordan dies at 76

Pharmacologist V. Craig Jordan, a professor of Breast and Medical Oncology and Molecular and Cellular Oncology at The University of Texas MD Anderson Cancer Center who discovered selective estrogen receptor modulators and developed breakthrough breast cancer treatments, died June 9 at his home in Houston.

June 14, 2024

Vol.50 No.24

By MD Anderson Cancer Center staff

Clinical Trials & Tribulations

The thorny road to drug approval for myelodysplastic syndromes

At the recent ASCO annual meeting, within hematologic malignancies, therapies for multiple myeloma stole the show, comme d’habitude.

June 14, 2024

Vol.50 No.24

By Mikkael A. Sekeres

Guest Editorial

Cancer centers, health providers should clearly signal that they welcome LGBTQI+ patients

So far in 2024, 516 anti-queer bills have been introduced in state legislatures across the country, part of a coordinated effort where bills getting traction in one state are soon parroted by legislators in others.

June 14, 2024

Vol.50 No.24

By NFN Scout

In the Archives

In an interview and a memoir, V. Craig Jordan spoke about his life and SERMs

V. Craig Jordan, a pharmacologist who discovered selective estrogen receptor modulators, died on June 9. Jordan, a professor at The University of Texas MD Anderson Cancer Center who was credited with discovery of tamoxifen, was 76. An obituary appears in this issue. Jordan appeared on the Cancer History Project podcast in 2022 to discuss...

June 14, 2024

Vol.50 No.24